Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care

References

• Cattaneo D, Capetti A, Rizzardini G. Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opin Drug Metab Toxicol. 2019;15(3):245–252. doi:10.1080/17425255.2019.1577821
   PubMed Web of Science ®Google Scholar
• Diaco ND, Strickler C, Giezendanner S, Wirz SA, Tarr PE. Systematic de-escalation of successful triple antiretroviral therapy to dual therapy with dolutegravir plus emtricitabine or lamivudine in Swiss HIV-positive persons. EClinicalMedicine. 2018;6:21–25. doi:doi:10.1016/j.eclinm.2018.11.005
   PubMedGoogle Scholar
• Pérez-González A, Suárez-García I, Ocampo A, Poveda E. Two-drug regimens for HIV - current evidence, research gaps and future challenges. Microorganisms. 2022;10(2):433.
   PubMed Web of Science ®Google Scholar
• Baril JG, Angel JB, Gill MJ, et al. Dual therapy treatment strategies for the management of patients infected with HIV: a systematic review of current evidence in ARV-naive or ARV-experienced, virologically suppressed patients. PLoS One. 2016;11(2):e0148231. doi:10.1371/journal.pone.0148231
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration (FDA). FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment - Dovato Updated April 08, 2019. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-two-drug-complete-regimen-hiv-infected-patients-who-have-never-received. Accessed April 11, 2024.
   Google Scholar
• U.S. Food & Drug Administration (FDA). FDA approved changes to the DOVATO (dolutegravir/lamivudine) product labeling. Available from: https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approved-changes-dovato-dolutegravirlamivudine-product-labeling. Accessed December 23, 2021.
   Google Scholar
• Osiyemi O, De Wit S, Ajana F, et al. efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide–based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 From the Phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2022;75(6):975–986. doi:10.1093/cid/ciac036
   PubMed Web of Science ®Google Scholar
• Llibre JM, Brites C, Cheng C-Y, et al. Efficacy and safety of switching to the 2-drug regimen dolutegravir/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial. Clin Infect Dis. 2022;76(4):720–729. doi:10.1093/cid/ciac130
   Web of Science ®Google Scholar
• Rial-Crestelo D, de Miguel R, Montejano R, et al. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: week 96 results of ART-PRO pilot study. J Antimicrob Chemother. 2020;76(3):738–742. doi:10.1093/jac/dkaa479
   Web of Science ®Google Scholar
• Li JZ, Sax PE, Marconi VC, et al. No significant changes to residual viremia after switch to dolutegravir and lamivudine in a randomized trial. Open Forum Infect Dis. 2019;6(3). doi:10.1093/ofid/ofz056
   Web of Science ®Google Scholar
• van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243
   PubMed Web of Science ®Google Scholar
• Patel R, Evitt L, Mariolis I, et al. HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review. Infect Dis Ther. 2021;10(4):2051–2070. doi:10.1007/s40121-021-00522-7
   PubMed Web of Science ®Google Scholar
• Punekar YS, Parks D, Joshi M, et al. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. HIV Med. 2021;22(6):423–433. doi:doi:10.1111/hiv.13050
   PubMed Web of Science ®Google Scholar
• Suárez-García I, Alejos B, Hernando V, et al. Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice. J Antimicrob Chemother. 2023;78(6):1423–1432. doi:10.1093/jac/dkad102
   PubMed Web of Science ®Google Scholar
• Martínez-Serra A, De Lazzari E, Berrocal L, et al. Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study. J Antimicrob Chemother. 2023;78(8):1955–1962. doi:10.1093/jac/dkad189
   PubMed Web of Science ®Google Scholar
• Dueñas-Gutiérrez C, Buzón L, Pedrero-Tomé R, et al. Efficacy and safety of two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 virologically suppressed people living with HIV. Viruses. 2023;15(4):936.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Gulminetti R, Pagnucco L, et al. Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2022;22(1):782. doi:10.1186/s12879-022-07769-6
   PubMed Web of Science ®Google Scholar
• Borghetti A, Alkhatib M, Dusina A, et al. Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study. J Antimicrob Chemother. 2021;77(3):740–746. doi:10.1093/jac/dkab429
   Web of Science ®Google Scholar
• Gagliardini R, Lorenzini P, Cozzi-Lepri A, et al. Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures. J Global Antimicrob Resist. 2023;32:158–163. doi:doi:10.1016/j.jgar.2022.11.010
   PubMed Web of Science ®Google Scholar
• Ciccullo A, Borghi V, Giacomelli A, et al. Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. J Acquir Immune Defic Syndr. 2021;88:3.
   Web of Science ®Google Scholar
• Nasreddine R, Yombi JC, Darcis G, et al. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium. HIV Med. 2022:1. doi:10.1111/hiv.13373
   Web of Science ®Google Scholar
• Baldin G, Ciccullo A, Rusconi S, et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54(6):728–734. doi:doi:10.1016/j.ijantimicag.2019.09.002
   PubMed Web of Science ®Google Scholar
• Borghetti A, Baldin G, Lombardi F, et al. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018;19(7):452–454. doi:doi:10.1111/hiv.12611
   Web of Science ®Google Scholar
• Mendoza I, Lázaro A, Torralba M. Effectiveness, durability, and safety of dolutegravir and lamivudine versus dolutegravir, lamivudine, and abacavir in a real-life cohort of HIV-infected adults. Ann. Pharmacother. 2022;56(4):412–421. doi:10.1177/10600280211034176
   PubMed Web of Science ®Google Scholar
• Mazzitelli M, Sasset L, Gardin S, et al. Real-life experience on dolutegravir and lamivudine as initial or switch therapy in a silver population living with HIV. Viruses. 2023;15(8):1740.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Legnani G, Cretella S, Bon I, Viale P. Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people living with HIV-1 aged over 65 years. AIDS Res Hum Retroviruses. 2023. doi:10.1089/aid.2023.0046
   PubMed Web of Science ®Google Scholar
• Greenberg L, Ryom L, Wandeler G, et al. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting. J Acquir Immune Defic Syndr. 2020;83(3):240–250. doi:10.1097/qai.0000000000002250
   PubMed Web of Science ®Google Scholar
• Korten V, Gökengin D, Eren G, et al. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011–2017. AIDS Res Ther. 2021;18(1):4. doi:10.1186/s12981-020-00328-6
   PubMed Web of Science ®Google Scholar
• Elion RA, Dunbar M, Amico KR, et al. Exploring Antiretroviral Therapy (ART) switch decisions in clinical setting: trio health mixed methods study. Open Forum Infect Dis. 2023;10(Supplement_2):1. doi:10.1093/ofid/ofad500.1405
   Google Scholar
• Gelhorn H, Garris C, Arthurs E, et al. Patient and physician preferences for regimen attributes for the treatment of HIV in the United States and Canada. J Personal Med. 2022;12(3):334.
   PubMed Web of Science ®Google Scholar
• D’arminio Monforte A, Tavelli A, Sala M, et al. Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study. J Antimicrob Chemother. 2023;78(4):933–945. doi:10.1093/jac/dkad026
   PubMed Web of Science ®Google Scholar
• ViiV Healthcare. DOVATO Prescribing Information. North CArolina, US: ViiV Healthcare; 2009.
   Google Scholar
• Meyer D, Slone SE, Ogungbe O, Duroseau B, Farley JE. Impact of the COVID-19 pandemic on HIV healthcare service engagement, treatment adherence, and viral suppression in the United States: a systematic literature review. AIDS Behav. 2022. doi:10.1007/s10461-022-03771-w
   Web of Science ®Google Scholar
• Pierone GJ, Fusco JS, Brunet L, et al. The impact of the COVID-19 pandemic on clinical follow-up, monitoring and regimen discontinuation for people living with HIV in the US; 2021.
   Google Scholar
• Centers for Disease Control and Prevention. HIV surveillance report; 2020. Available from: https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed September 15, 2022.
   Google Scholar